Testing effectiveness (Phase 2)Study completedNCT01730612
What this trial is testing
ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
Who this might be right for
HER2 Negative Breast Carcinoma Expressing CEA
Nantes University Hospital 23